MetaCap

Compass Therapeutics Inc. Company Profile

NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.6882+0.0097 (+1.43%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Compass Therapeutics at a glance

Compass Therapeutics Inc. (NASDAQ: CMPX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Compass Therapeutics is led by Dr. Thomas J. Schuetz M.D., Ph.D. and employs about 39 people. At a market capitalization of $122.2 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001738021, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Compass Therapeutics do?

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Compass Therapeutics Inc.
Ticker
NASDAQ: CMPX
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Thomas J. Schuetz M.D., Ph.D.
Employees
39
Headquarters
80 Guest Street, Boston, MA, United States
Phone
617 500 8099
Market cap
$122.19M
SEC CIK
0001738021
Latest annual report
10-K · Mar 5, 2026

Companies similar to Compass Therapeutics

CMPX peer companies
CompanyPrice% ChgMarket capCompare
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs CMPX
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs CMPX
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs CMPX
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs CMPX
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs CMPX
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs CMPX
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs CMPX
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs CMPX

Related